TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: PCDSO    
Pain Clinic Drug Screen, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, methadone, opiates, phencyclidine, and tetrahydrocannabinol

 

Detection and identification of prescription or over-the-counter drugs frequently found in drug overdose or used with a suicidal intent

 

This test is intended to be used in a setting where the identification of the drug is required.

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods (gas chromatography-flame ionization detector for ethanol; gas chromatography-mass spectrometry for barbiturates, benzodiazepines, cocaine and metabolites, methadone, phencyclidine, and tetrahydrocannabinol metabolite; liquid chromatography-tandem mass spectrometry for amphetamines and opiates) at an additional charge. If only oxycodone screens positive, only confirmation of oxycodone w/metabolite will be performed. Any other opiate- positive screen will result in the full opiate confirmation being performed.

 

The drug screen, prescription/OTC will be performed by gas chromatography-mass spectrometry. Qualitative results will be reported.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

This panel was designed to screen for and confirm by gas chromatography-mass spectrometry (GC-MS) or gas chromatography-flame ionization detection (GC-FID) the following drugs:

-Barbiturates

-Benzodiazepines

-Cocaine

-Ethanol

-Methadone

-Phencyclidine

-Tetrahydrocannabinol

 

Confirmation by liquid chromatograph-tandem mass spectrometry (LC-MS/MS) is completed for all opiates and amphetamines.

 

This panel uses the screening technique which involves immunoassay testing for drugs by class. All positive screening results are confirmed by GC-MS, GC-FID, or LC-MS/MS, and quantitated, before a positive result is reported.

 

The panel includes PDSU / Drug Screen, Prescription/OTC, Urine, which looks for a broad spectrum of prescription and over-the-counter drugs. It is designed to detect drugs that have toxic effects, as well as known antidotes or active therapies that a clinician can initiate to treat the toxic effect. The test is intended to help physicians manage an apparent overdose or intoxicated patient, to determine if a specific set of symptoms might be due to the presence of drugs, or to evaluate a patient who might be abusing these drugs intermittently. The test is not designed to screen for intermittent use of illicit drugs.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Screening cutoff concentrations:

Amphetamines: 500 ng/mL

Barbiturates: 200 ng/mL

Benzodiazepines: 100 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Ethanol: 10 mg/dL

Methadone metabolite: 300 ng/mL

Opiates: 300 ng/mL

Phencyclidine: 25 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Interpretation Provides information to assist in interpretation of the test results

A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU / Amphetamines Confirmation, Urine) for more information.

 

For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at https://www.mayocliniclabs.com/test-info/drug-book/index.html.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Not intended for use in employment-related testing.

 

For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. See PDSOX / Pain Clinic Drug Screen, Chain-of-Custody, Urine.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Physicians' Desk Reference. 61st edition. Montvale, NJ. Thomson, 2007

2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th edition. New York, NY. McGraw-Hill Professional, 2001

3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company. 2011, pp 1109-1188

4. Principles of Forensic Toxicology. Second edition. Washington, DC. AACC Press, 2003, p 385